Skip to main content
VISEN Pharmaceuticals logo

VISEN Pharmaceuticals — Investor Relations & Filings

Ticker · 2561 ISIN · KYG9363A1003 LEI · 254900OJ8HIP6GRV1044 HKEX Manufacturing
Open in API
Filings indexed 67 across all filing types
Latest filing 2025-04-30 Proxy Solicitation & In…
Country KY Cayman Islands
Listing HKEX 2561

About VISEN Pharmaceuticals

http://www.visenpharma.com

VISEN Pharmaceuticals is an innovative biopharmaceutical company focused on the development and commercialization of paradigm-shifting therapies for endocrine diseases. The company is committed to addressing unmet medical needs within the Greater China market by providing innovative treatments and compassionate patient care. VISEN's core strategy involves leveraging advanced drug delivery platforms, which utilize prodrugs connected to carrier molecules via a linker structure. This technology enables the controlled, slow release of the unmodified prototype drug, ensuring sustained therapeutic action while the linker and carrier are safely excreted. VISEN serves as a key strategic partner for global biopharma companies seeking to commercialize high-quality endocrine assets in the region.

Recent filings

Filing Released Lang Actions
(1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS&#x3b; (2) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES AND SELL OR TRANSFER TREASURY SHARES&#x3b; (3) PROPOSED RE-APPOI
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal circular issued by VISEN Pharmaceuticals to its shareholders. It contains the agenda for the upcoming Annual General Meeting (AGM), including proposals for the re-election of directors, granting of general mandates for share repurchase and issuance, and the re-appointment of auditors. It also includes a notice of the AGM and a proxy form. This content is characteristic of a Proxy Solicitation & Information Statement (PSI) sent to shareholders to provide information and request votes for an upcoming meeting.
2025-04-30 English
2024 Annual Report
Annual Report Classification · 100% confidence The document is explicitly titled '2024 Annual Report' and contains standard sections such as 'Corporate Information', 'CEO's Statement', 'Financial Highlights', 'Management Discussion and Analysis', and 'Independent Auditor's Report'. It provides comprehensive financial statements and business reviews for the fiscal year, fitting the definition of a 10-K (Annual Report). FY 2024
2025-04-30 English
Notification Letter to Non-registered Shareholders and Reply Form
Report Publication Announcement Classification · 85% confidence The document is a notice to non-registered shareholders announcing the Company’s adoption of electronic dissemination of corporate communications (e.g., directors’ report, annual accounts, interim report, notices, circulars, proxy forms) and instructing how to access future reports on the Company and HKExnews websites or request printed copies. It does not contain any substantive financial content itself but rather announces how and where future reports will be published. Under the “menu vs meal” rule, this is not the report itself but an announcement about the publication and distribution method of corporate communications. This matches the definition of a Report Publication Announcement (RPA).
2025-04-25 English
Notification Letter to Registered Shareholders and Reply Form
Regulatory Filings Classification · 85% confidence The document is a letter to shareholders notifying them of the adoption of electronic dissemination of corporate communications under the Hong Kong Listing Rules and soliciting email/contact details. It is not the content of an annual or interim report, not a proxy statement or voting result, nor an earnings release – rather it is a compliance/regulatory announcement regarding how future communications will be delivered. It does not itself contain substantive financial results or governance rules, but is a general regulatory notification. Therefore, it best fits the fallback category “Regulatory Filings (RNS).”
2025-04-25 English
STABILIZING ACTIONS, END OF STABILIZATION PERIOD AND LAPSE OF THE OVER-ALLOTMENT OPTION
Share Issue/Capital Change Classification · 85% confidence The document is an announcement under Hong Kong listing rules detailing stabilizing actions taken in connection with a Global Offering, the end of the stabilization period, and the lapse of the over-allotment option — all of which relate directly to the company’s share issuance and capital raising process. It is not an AGM presentation, earnings release, or annual/interim report, nor is it a simple notice of publication. Instead, it provides an update on the capital markets activity (IPO stabilization and share overallotment) tied to the company’s fundraising. This falls squarely under the Share Issue/Capital Change category.
2025-04-17 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025
Regulatory Filings Classification · 85% confidence The document is a statutory monthly return (Form FF301) submitted to the Hong Kong Stock Exchange under its Listing Rules, detailing movements in authorised share capital, issued shares, treasury shares and related confirmations. It is not a presentation, earnings release, or proxy statement, nor a standalone capital market transaction announcement; rather it is a regulatory compliance filing. No other more specific category applies, so it falls under the fallback category of Regulatory Filings (RNS).
2025-04-07 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.